Statement Of Cash Flows [Abstract]

Cinclus Pharma Holding AB - Filing #5879291

Concept 2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
As at
2024-12-31
2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
As at
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
As at
2022-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Profit (loss)
168 031 SEK
SEK
SEK
SEK
168 031 SEK
SEK
SEK
215 118 SEK
215 118 SEK
SEK
Adjustments to reconcile profit (loss) [abstract]
Adjustments for increase (decrease) in trade accounts payable
2 480 SEK
546,000 SEK
Adjustments for depreciation and amortisation expense
1 338 SEK
1 251 SEK
Adjustments for unrealised foreign exchange losses (gains)
251,000 SEK
25,000 SEK
Adjustments for share-based payments
2 870 SEK
2 444 SEK
Interest paid, classified as operating activities
349,000 SEK
453,000 SEK
Interest received, classified as operating activities
11 271 SEK
2 912 SEK
Cash flows from (used in) operating activities
178 367 SEK
209 186 SEK
Cash flows from (used in) financing activities [abstract]
Proceeds from issuing shares
715 000 SEK
SEK
Payments of lease liabilities, classified as financing activities
1 376 SEK
1 284 SEK
Cash flows from (used in) financing activities
655 200 SEK
122 892 SEK
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes
476 833 SEK
86 294 SEK
Effect of exchange rate changes on cash and cash equivalents [abstract]
Effect of exchange rate changes on cash and cash equivalents
1 912 SEK
720,000 SEK
Cash and cash equivalents
566 716 SEK
87 972 SEK
173 546 SEK

Talk to a Data Expert

Have a question? We'll get back to you promptly.